Sean E. Harper
Chief Executive Officer bij Amgen Rockville, Inc.
Profiel
Sean E.
Harper is a businessperson who has been at the head of 5 different companies and occupies the position of Chairman at 3T Biosciences, Inc., Chairman of Dantari, Inc., Co-Founding Managing Director at Westlake Biopartners LLC and President, Chief Executive Officer & Director at Amgen Rockville, Inc. He is also on the board of Jamanda Ltd.
He previously was Executive Vice President-Research & Development at Amgen, Inc. Chief Executive Officer for Onyx Pharmaceuticals, Inc. and President & Director at BioVex Group, Inc. (both are subsidiaries of Amgen, Inc.) and Senior Director-Clinical Genomics at Merck Research Laboratories Massachusetts LLC.
He received a doctorate from the University of California, Berkeley.
Actieve functies van Sean E. Harper
Bedrijven | Functie | Begin |
---|---|---|
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Chief Executive Officer | 02-03-2012 |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | Private Equity Investor | 01-01-2019 |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | Director/Board Member | - |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | Chairman | 25-08-2022 |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Chairman | - |
Eerdere bekende functies van Sean E. Harper
Bedrijven | Functie | Einde |
---|---|---|
AMGEN INC. | Chief Tech/Sci/R&D Officer | - |
ACELYRIN, INC. | Director/Board Member | - |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | President | - |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Executive Officer | - |
░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Opleiding van Sean E. Harper
University of California, Berkeley | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
AMGEN INC. | Health Technology |
ACELYRIN, INC. | Health Technology |
Bedrijven in privébezit | 8 |
---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
BioVex Group, Inc.
BioVex Group, Inc. BiotechnologyHealth Technology BioVex Group, Inc. operates as a clinical-stage biotechnology company. It focuses on the development and commercialization of targeted treatments for cancer and the prevention of infectious disease. The company was founded in 1999 and is headquartered in Woburn, MA. | Health Technology |
Amgen Rockville, Inc.
Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Part of Merck & Co., Inc., Merck Research Laboratories Massachusetts LLC is a pharmaceutical company that provides free medicines and adult vaccines to qualified patients through their Merck Patient Assistance Program. The private company is based in Boston, MA and is a part of Merck & Co., Inc. and its affiliates. The company also offers information about insurance coverage and financial assistance options for eligible patients. The company conducts clinical trials and provides medical information covering thousands of topics in all fields of medicine through their Merck Manuals. Additionally, they report on their commitment to operating responsibly to benefit society through their corporate responsibility program, which includes their environmental, social, and governance (ESG) report. Merck for Mothers is an initiative to create a world where no woman has to die giving life. | Health Technology |
3T Biosciences, Inc.
3T Biosciences, Inc. BiotechnologyHealth Technology 3T Biosciences, Inc. operates as immunotherapy company. The company was founded by Luke J. Lee, Marvin Gee and Leah Sibener and is headquartered in Palo Alto, CA. | Health Technology |
Westlake Biopartners LLC
Westlake Biopartners LLC Investment ManagersFinance Westlake Biopartners LLC (Westlake Biopartners) is a venture capital firm founded in 2018. The firm is headquartered in Westlake Village, California. | Finance |
Jamanda Ltd.
Jamanda Ltd. Financial ConglomeratesFinance Jamanda Ltd. is an investment holding British company founded in 2016. The private company is based in Grantham, UK. The company's main function is to hold investments. | Finance |
Dantari, Inc.
Dantari, Inc. BiotechnologyHealth Technology Dantari, Inc. is a clinical-stage biotechnology company located in Thousand Oaks, CA. Dantari is focused on developing targeted therapeutics for the treatment of cancers and other diseases. The company is advancing a pipeline of T-HDC (Targeted High-Capacity Drug Conjugate) chemotherapeutic agents and next-generation antibody-drug conjugate (ADC) therapeutics. Dantari's HDC and T-HDC platform technology uses chemically defined polymers with a high drug-antibody ratio (DAR) and a high degree of control and flexibility to optimize performance of targeted drug conjugates that can leverage validated targets across a broad range of therapeutic payload options. The company's technology enables a significantly higher drug-to-antibody ratio compared to traditional ADCs and provides further benefit by incorporating tunable release of payload. The company was founded in 2018 by CEO Richard A. Markus. | Health Technology |